Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 66, Iss. 12, 2014-12 ,pp. : 3255-3264

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 2a randomized, double‐blind, placebo‐controlled, sequential dose‐escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate‐to‐severe psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 3, 2015-09 ,pp. : 767-776

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 2a randomized, double‐blind, placebo‐controlled, sequential dose‐escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate‐to‐severe psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 7-0963, Iss. 3, 2015-09 ,pp. : 767-776

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double‐blind, randomized, placebo‐controlled, phase III studies

By  

BJU INTERNATIONAL, Vol. 116, Iss. 4, 2015-10 ,pp. : 650-656

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tofacitinib withdrawal and retreatment in moderate‐to‐severe chronic plaque psoriasis: a randomized controlled trial

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 5, 2015-05 ,pp. : 1395-1406

John Wiley & Sons Inc

Access to resources Recommend Favorite